AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30947737 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice A: a stacked telephone system and promoting community transport.
Number of subjects: 34
Study 30947737 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice B: signposting to community transport, appointment flexibility, mobility scooter charging point, and promoting the role of receptionists.
Number of subjects: 34
Study 30947737 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice C: local taxi firm partnership and training receptionists.
Number of subjects: 34
Study 30947737 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 34
Study 29736007 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 12 weeks
Number of subjects: 63
Study 29736007 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 63
Study 26943612 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) volume above the median
Number of subjects: 201
Study 26943612 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) density above the median
Number of subjects: 201
Study 26943612 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal vesicle involvement
Number of subjects: 201
Study 26943612 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 201
Study 24345080 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptoglobin phenotype (1-1, 2-1, 2-2)
Number of subjects: 2184
Study 22784348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ageratina pichinchensis extract (0.76%)
Number of subjects: 160
Study 22784348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ageratina pichinchensis extract (1.52%)
Number of subjects: 160
Study 22784348 — intervention group
Group type: COMPARATOR
Intervention: 2% ketoconazole
Number of subjects: 160
Study 20124509 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, lenalidomide, and dexamethasone maintenance for 3 years
Number of subjects: 480
Study 20124509 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib, thalidomide, and dexamethasone in year 1 and thalidomide/dexamethasone in years 2 and 3
Number of subjects: 480
Study 20124509 — intervention group
Group type: EXPERIMENTAL
Intervention: GEP-defined high-risk designation
Number of subjects: 480
Study 20124509 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical modeling of CRD in low-risk myeloma
Number of subjects: 480
Study 20124509 — intervention group
Group type: EXPERIMENTAL
Intervention: CCND1 without CD20 myeloma
Number of subjects: 480
Study 16729880 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint mobilisation twice a week for four weeks
Number of subjects: 90
Study 16729880 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise programme
Number of subjects: 90
Study 16729880 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint mobilisation
Number of subjects: 90
Study 16729880 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint mobilisation and standard exercise programme
Number of subjects: 90
Study 15499515 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in smoking cessation counselling
Number of subjects: 642
Study 15499515 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level
Number of subjects: 642
Study 15499515 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of change
Number of subjects: 642
Study 11737044 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot, humid air (HHA: 37 degrees C, > 95% relative humidity)
Number of subjects: 20
Study 11737044 — intervention group
Group type: COMPARATOR
Intervention: Room air (25 degrees C, 30% RH)
Number of subjects: 20
Study 9159724 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment for 10 weeks
Number of subjects: 29
Study 9159724 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific psychological treatment (control) for 10 weeks
Number of subjects: 29
Study 9159724 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 29
Study 9159724 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific psychological treatment (control)
Number of subjects: 29
Study 8292465 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg quinapril
Number of subjects: 2242
Study 8292465 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg quinapril
Number of subjects: 2242
Study 8292465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2242
Study 3541830 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (up to 5 mg/kg/d)
Number of subjects: 53
Study 3541830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 3541830 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine plus desipramine (plasma level study)
Number of subjects: 53
Study 3541830 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive hallucinations during the episode
Number of subjects: 53
Study 3541830 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-corrected imipramine dosage
Number of subjects: 53
Study 3541830 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 53
Study 31910896 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamalakyadi decoction (TMD12)
Number of subjects: 0
Study 31910896 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried formulation of Tamalakyadi decoction
Number of subjects: 0
Study 31910896 — intervention group
Group type: COMPARATOR
Intervention: Antihistamine loratadine (control)
Number of subjects: 0
Study 29417614 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 1997
Study 29417614 — intervention group
Group type: COMPARATOR
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 1997
Study 27977600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 2.0 μg/kg + dexmedetomidine 2.0 μg/kg (group S2)
Number of subjects: 80
Study 27977600 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 0.15 mg/kg + dexmedetomidine 2.0 μg/kg (group N2)
Number of subjects: 80
Study 27977600 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 0.15 mg/kg + dexmedetomidine 1.5 μg/kg (group N1)
Number of subjects: 80
Study 27977600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 2.0 μg/kg + dexmedetomidine 1.5 μg/kg (group S1)
Number of subjects: 80
Study 23624699 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical APF gel (1.23 % F, pH 3.5, for 4 min)
Number of subjects: 60
Study 23624699 — intervention group
Group type: EXPERIMENTAL
Intervention: Er, Cr:YSGG laser (P:0.25 W, E:12.5 mJ, RR:20 Hz, PD:140 μs, 11 % air, without water, for 10 s)
Number of subjects: 60
Study 23624699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride + laser group (F + L)
Number of subjects: 60
Study 23624699 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 60
Study 22048714 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 381
Study 22048714 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 381
Study 22048714 — intervention group
Group type: EXPERIMENTAL
Intervention: F/V diet
Number of subjects: 381
Study 20075768 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for degenerative spondylolisthesis (DS)
Number of subjects: 1235
Study 20075768 — intervention group
Group type: COMPARATOR
Intervention: Surgery for spinal stenosis (SPS)
Number of subjects: 1235
Study 20075768 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment for both DS and SPS
Number of subjects: 1235
Study 17942179 — intervention group
Group type: COMPARATOR
Intervention: Cognitive task requiring little attention (forward counting)
Number of subjects: 64
Study 17942179 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly demanding cognitive task (arithmetic manipulation)
Number of subjects: 64
Study 15533612 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated omega3 fatty acids (LCn3) from oil-rich fish
Number of subjects: 0
Study 15533612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice to eat more oil-rich fish or take LCn3 supplements
Number of subjects: 0
Study 12812661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of immunotoxin (IT) once a week for 8 weeks and then once every month for 8 months
Number of subjects: 128
Study 12812661 — intervention group
Group type: COMPARATOR
Intervention: Calmette‐Guerin vaccine (BCG) once a week for 8 weeks and then once every month for 8 months
Number of subjects: 128
Study 12812661 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin (MMC) once a week for 8 weeks and then once every month for 8 months
Number of subjects: 128
Study 11061615 — intervention group
Group type: EXPERIMENTAL
Intervention: BIP + RT (bleomycin 30 units/24‐hour infusion, ifosfamide 5 g/m2/24 hours, cisplatin 50 mg/m2 followed by pelvic radiotherapy)
Number of subjects: 172
Study 11061615 — intervention group
Group type: COMPARATOR
Intervention: RT (pelvic radiotherapy alone)
Number of subjects: 172
Study 11061615 — intervention group
Group type: EXPERIMENTAL
Intervention: BIP + RT
Number of subjects: 172
Study 11061615 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 172
Study 9293972 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (mean dose 46/69 mg/day after 7 days/4 weeks)
Number of subjects: 208
Study 9293972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 9293972 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 208
Study 8297841 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 71
Study 8297841 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 71
Study 3550679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 30
Study 3550679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31997543 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric intervention programme (CGIP) - Class-styled (CS) sessions
Number of subjects: 526
Study 31997543 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive geriatric intervention programme (CGIP) - Home-based (HB) programme
Number of subjects: 526
Study 29656937 — intervention group
Group type: EXPERIMENTAL
Intervention: MynxGrip®
Number of subjects: 208
Study 29656937 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 208
Study 26963569 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored physical training and activity for 3 months
Number of subjects: 322
Study 26963569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 322
Study 23768518 — intervention group
Group type: EXPERIMENTAL
Intervention: Mega-dose vitamin A supplementation (MVAS) of 60 mg administered at diagnosis and again after 1 month.
Number of subjects: 262
Study 23322206 — intervention group
Group type: COMPARATOR
Intervention: FLO (infusional 5-FU, leucovorin, and oxaliplatin)
Number of subjects: 44
Study 23322206 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOT (infusional 5-FU, leucovorin, oxaliplatin, and docetaxel 50 mg/m²)
Number of subjects: 44
Study 23322206 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FLO and FLOT
Number of subjects: 44
Study 20626444 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of a gel containing allium cepa, allantoin, and pentaglycan twice a day for 24 weeks
Number of subjects: 30
Study 20626444 — intervention group
Group type: COMPARATOR
Intervention: No topical treatments
Number of subjects: 30
Study 18955038 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial attention
Number of subjects: 0
Study 18955038 — intervention group
Group type: EXPERIMENTAL
Intervention: Object-based attention
Number of subjects: 0
Study 18955038 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral cueing
Number of subjects: 0
Study 18955038 — intervention group
Group type: EXPERIMENTAL
Intervention: Central cueing
Number of subjects: 0
Study 16508264 — intervention group
Group type: EXPERIMENTAL
Intervention: 36% phosphoric acid gel for 1 min
Number of subjects: 44
Study 16508264 — intervention group
Group type: EXPERIMENTAL
Intervention: 36% phosphoric acid gel for 4 min
Number of subjects: 44
Study 16508264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated salt
Number of subjects: 44
Study 16508264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel
Number of subjects: 44
Study 16508264 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival bleeding
Number of subjects: 44
Study 16508264 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltaQ
Number of subjects: 44
Study 12953945 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v in combination with metronidazole
Number of subjects: 20
Study 12953945 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with metronidazole
Number of subjects: 20
Study 14564593 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: low loading dose and high demand bolus
Number of subjects: 21
Study 14564593 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: high loading dose and demand bolus
Number of subjects: 21
Study 14564593 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: high loading dose and low demand bolus
Number of subjects: 21
Study 8961467 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic model for binary data assessment
Number of subjects: 0
Study 1387484 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 2963
Study 1387484 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Control
Number of subjects: 2963
Study 1387484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2963
Study 6365104 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg tulobuterol
Number of subjects: 0
Study 6365104 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg fenoterol
Number of subjects: 0
Study 30879366 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous probiotics (1 capsule daily for 6 weeks after 7 days of clindamycin 2% vaginal cream)
Number of subjects: 273
Study 30879366 — intervention group
Group type: COMPARATOR
Intervention: Interrupted probiotics (1 capsule twice a week for 6 weeks after 7 days of clindamycin 2% vaginal cream)
Number of subjects: 273
Study 30879366 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous probiotics
Number of subjects: 273
Study 30879366 — intervention group
Group type: COMPARATOR
Intervention: Interrupted probiotics
Number of subjects: 273
Study 29648571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dads And Daughters Exercising and Empowered (DADEE) program
Number of subjects: 268
Study 29648571 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 268
Study 29117153 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized constant-modulus (CM) waveforms (arbitrary-phase and QPSK) designed through a customized Gaussian randomization method.
Number of subjects: 0
Study 29117153 — intervention group
Group type: COMPARATOR
Intervention: LFM waveforms
Number of subjects: 0
Study 26158415 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation (RD)
Number of subjects: 30
Study 26158415 — intervention group
Group type: COMPARATOR
Intervention: Cotton rolls/retraction cord isolation (CR/RC)
Number of subjects: 30
Study 23797529 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 30
Study 23797529 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (graft rejection reactions and infections)
Number of subjects: 30
Study 21704889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized house dust mite extract
Number of subjects: 134
Study 19770374 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (cisplatin and fluorouracil)
Number of subjects: 802
Study 19770374 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 802
Study 16532765 — intervention group
Group type: EXPERIMENTAL
Intervention: Controller for skeletal muscle relaxation using mivacurium
Number of subjects: 0
Study 16532765 — intervention group
Group type: COMPARATOR
Intervention: Anesthesiologist's manual control
Number of subjects: 0
Study 15307543 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular Adsorbent Recirculating System (MARS) for 3 consecutive days; continued if bilirubin > 6 mg/dl
Number of subjects: 27
Study 15307543 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (non-MARS group)
Number of subjects: 27
Study 10903236 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust particulates (DEP) at a concentration of 200 microg/m(3) PM(10) for 2 hours
Number of subjects: 10
Study 10903236 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 10
Study 10903236 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust particulates (DEP)
Number of subjects: 10
Study 9052301 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg) plus ketamine (60 mg) administered preoperatively (Group 1)
Number of subjects: 60
Study 9052301 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (2 mg) plus ketamine (60 mg) administered postoperatively (Group 2)
Number of subjects: 60
Study 8110072 — intervention group
Group type: EXPERIMENTAL
Intervention: rh‐EPO treatment for 12 months
Number of subjects: 38
Study 8110072 — intervention group
Group type: EXPERIMENTAL
Intervention: rh‐EPO treatment for 24 months
Number of subjects: 38
Study 2874663 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg daily)
Number of subjects: 17
Study 2874663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31023258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 22
Study 31023258 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 22
Study 27839988 — intervention group
Group type: EXPERIMENTAL
Intervention: Western Lyric (WL) singers
Number of subjects: 54
Study 27839988 — intervention group
Group type: COMPARATOR
Intervention: Musical Theater (MT) singers
Number of subjects: 54
Study 27839988 — intervention group
Group type: EXPERIMENTAL
Intervention: Long‐term average spectrum analysis
Number of subjects: 54
Study 25493460 — intervention group
Group type: EXPERIMENTAL
Intervention: eSVS Mesh (treated saphenous vein)
Number of subjects: 90
Study 25493460 — intervention group
Group type: COMPARATOR
Intervention: Unsupported saphenous vein (control)
Number of subjects: 90
Study 23731437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictures of stimuli with different levels of fear-relevance presented with scared faces
Number of subjects: 0
Study 23731437 — intervention group
Group type: COMPARATOR
Intervention: Pictures of stimuli with different levels of fear-relevance presented alone
Number of subjects: 0
Study 21147097 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (3.66-8000 ng/min)
Number of subjects: 75
Study 21147097 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.0128-1000 ng/min)
Number of subjects: 75
Study 21147097 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined factors (finger temperature, BMI, age, phenylephrine sensitivity)
Number of subjects: 75
Study 19058926 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release (IR) methamphetamine (5mg, 6x/day)
Number of subjects: 82
Study 19058926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release (SR) methamphetamine (30 mg first pill, 1x/day; 0mg 5x/day)
Number of subjects: 82
Study 19058926 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0mg, 6x/day)
Number of subjects: 82
Study 16825088 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin E therapy (400 mg daily for 5 weeks)
Number of subjects: 29
Study 16825088 — intervention group
Group type: COMPARATOR
Intervention: No antioxidant supplementation (Control group)
Number of subjects: 29
Study 16825088 — intervention group
Group type: COMPARATOR
Intervention: Comparison with healthy controls (N=16)
Number of subjects: 29
Study 14961048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (VIAGRA)
Number of subjects: 152
Study 12881929 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18 g sucrose
Number of subjects: 271
Study 12881929 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.24 g sucrose (2 mL 12% sucrose)
Number of subjects: 271
Study 12881929 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 271
Study 9647414 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful late coronary angioplasty
Number of subjects: 113
Study 9647414 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 113
Study 9647414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction >0.4
Number of subjects: 113
Study 9647414 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-inferior myocardial infarction
Number of subjects: 113
Study 7857509 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg dried hypericum extract
Number of subjects: 12
Study 7857509 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg dried hypericum extract
Number of subjects: 12
Study 7857509 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg dried hypericum extract
Number of subjects: 12
Study 7857509 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 300 mg/day long-term dosing
Number of subjects: 12
Study 7857509 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose pharmacokinetics
Number of subjects: 12
Study 7857509 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of absorption lag-time
Number of subjects: 12
Study 7857509 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-response relationship
Number of subjects: 12
Study 2685652 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR (controlled‐release carbidopa/levodopa 50/200)
Number of subjects: 202
Study 2685652 — intervention group
Group type: COMPARATOR
Intervention: Sinemet (standard carbidopa/levodopa 25/100)
Number of subjects: 202
Study 1203882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus prednisone
Number of subjects: 41
Study 1203882 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, prednisone, and chloroquine
Number of subjects: 41